Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi Antero Janne, Alice Tsang Shaw, José Rodrigues Pereira et al. · The Lancet Oncology · 2012
Cited by 657 works. doi:10.1016/s1470-2045(12)70489-8
Authors
- Pasi Antero Janne
- Alice Tsang Shaw
- José Rodrigues Pereira
- Gaelle Jeannin
- Johan Vansteenkiste
- Carlos H. Barrios
- Fabio Andre Franke
- Lynda M Grinsted
- Victoria Zazulina
- Paul David Smith
- Lucio Crinò
References
- Global cancer statistics
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- ras oncogenes in human cancer: a review.
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy